$RSLS
ReShape Lifesciences Inc.

2024 Q1 Form 10-K Financial Statement

#000155837024004559 Filed on April 01, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $1.944M $1.982M $8.678M
YoY Change -15.0% -36.27% -22.79%
Cost Of Revenue $779.0K $140.0K $3.130M
YoY Change -26.72% -90.73% -29.47%
Gross Profit $1.165M $1.842M $5.548M
YoY Change -4.82% 15.13% -18.44%
Gross Profit Margin 59.93% 92.94% 63.93%
Selling, General & Admin $1.019M $2.998M $7.548M
YoY Change -53.3% -48.88% -46.44%
% of Gross Profit 87.47% 162.76% 136.05%
Research & Development $484.0K $739.0K $2.315M
YoY Change 6.84% 67.57% -8.75%
% of Gross Profit 41.55% 40.12% 41.73%
Depreciation & Amortization $6.000K $14.00K $121.0K
YoY Change -83.78% -97.28% -63.33%
% of Gross Profit 0.52% 0.76% 2.18%
Operating Expenses $3.375M $3.737M $20.93M
YoY Change -50.77% -40.74% -60.62%
Operating Profit -$2.210M -$1.895M -$15.38M
YoY Change -60.75% -59.73% -66.81%
Interest Expense $9.000K $114.0K $26.00K
YoY Change -280.0% -31.33% -123.01%
% of Operating Profit
Other Income/Expense, Net $25.00K $114.0K $122.0K
YoY Change 1150.0% 5600.0% 1009.09%
Pretax Income -$2.179M -$1.667M -$11.34M
YoY Change -17.71% -89.89% -75.67%
Income Tax $14.00K $31.00K $52.00K
% Of Pretax Income
Net Earnings -$2.193M -$1.698M -$11.39M
YoY Change -17.62% -89.78% -75.36%
Net Earnings / Revenue -112.81% -85.67% -131.22%
Basic Earnings Per Share -$0.09 -$1.91
Diluted Earnings Per Share -$0.09 -$0.11 -$1.91
COMMON SHARES
Basic Shares Outstanding 23.46M 13.14M 5.957M
Diluted Shares Outstanding 23.46M 5.957M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.379M $4.459M $4.459M
YoY Change -73.52% 15.67% 15.67%
Cash & Equivalents $2.379M $4.459M $4.459M
Short-Term Investments
Other Short-Term Assets $70.00K $126.0K $437.0K
YoY Change -58.33% 50.0% 64.91%
Inventory $3.467M $3.741M $3.741M
Prepaid Expenses
Receivables $1.600M $1.700M $1.659M
Other Receivables $26.00K $0.00 $0.00
Total Short-Term Assets $7.895M $10.30M $10.30M
YoY Change -48.16% 3.88% 3.88%
LONG-TERM ASSETS
Property, Plant & Equipment $54.00K $60.00K $310.0K
YoY Change -91.96% -91.4% -64.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $29.00K $29.00K $57.00K
YoY Change -49.12% -36.96% -44.12%
Total Long-Term Assets $336.0K $367.0K $367.0K
YoY Change -70.03% -70.19% -70.19%
TOTAL ASSETS
Total Short-Term Assets $7.895M $10.30M $10.30M
Total Long-Term Assets $336.0K $367.0K $367.0K
Total Assets $8.231M $10.66M $10.66M
YoY Change -49.66% -4.3% -4.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.314M $1.689M $1.689M
YoY Change -34.2% -12.31% -12.31%
Accrued Expenses $1.930M $1.814M $1.167M
YoY Change -63.71% -64.01% -71.47%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.519M $3.777M $3.777M
YoY Change -53.71% -49.51% -49.51%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $178.0K $223.0K $223.0K
YoY Change -82.06%
Total Long-Term Liabilities $178.0K $223.0K $223.0K
YoY Change -82.06%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.519M $3.777M $3.777M
Total Long-Term Liabilities $178.0K $223.0K $223.0K
Total Liabilities $3.697M $4.000M $4.000M
YoY Change -56.98% -46.53% -46.53%
SHAREHOLDERS EQUITY
Retained Earnings -$637.8M -$635.6M
YoY Change 1.74% 1.83%
Common Stock $23.00K $23.00K
YoY Change 666.67% 2200.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.534M $6.663M $6.663M
YoY Change
Total Liabilities & Shareholders Equity $8.231M $10.66M $10.66M
YoY Change -49.66% -4.3% -4.3%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$2.193M -$1.698M -$11.39M
YoY Change -17.62% -89.78% -75.36%
Depreciation, Depletion And Amortization $6.000K $14.00K $121.0K
YoY Change -83.78% -97.28% -63.33%
Cash From Operating Activities -$2.072M -$2.460M -$16.96M
YoY Change -59.06% -13.07% -22.56%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $3.000K $43.00K
YoY Change -100.0% -96.2% -67.18%
Acquisitions
YoY Change
Other Investing Activities $3.000K $33.00K
YoY Change -15.38%
Cash From Investing Activities $0.00 $0.00 -$10.00K
YoY Change -100.0% -100.0% -89.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $13.44M
YoY Change 2002.97%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 5.464M 17.57M
YoY Change -100.0% 756.43% 461.47%
NET CHANGE
Cash From Operating Activities -2.072M -2.460M -16.96M
Cash From Investing Activities 0.000 0.000 -10.00K
Cash From Financing Activities 0.000 5.464M 17.57M
Net Change In Cash -2.080M 3.004M 604.0K
YoY Change -140.56% -232.28% -103.2%
FREE CASH FLOW
Cash From Operating Activities -$2.072M -$2.460M -$16.96M
Capital Expenditures $0.00 $3.000K $43.00K
Free Cash Flow -$2.072M -$2.463M -$17.00M
YoY Change -59.12% -15.33% -22.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.91
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-108.90
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5956549
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
424390
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001427570
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23457047
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
519219
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.02
CY2023 us-gaap Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration
ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
CY2023 us-gaap Impairment Of Intangible Asset Finite Lived Statement Of Income Or Comprehensive Income Extensible Enumeration
ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
1-37897
CY2023 dei Entity Registrant Name
EntityRegistrantName
RESHAPE LIFESCIENCES INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1828101
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
18 Technology Dr. Suite 110
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Irvine
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92618
CY2023 dei City Area Code
CityAreaCode
949
CY2023 dei Local Phone Number
LocalPhoneNumber
429-6680
CY2023 dei Security12b Title
Security12bTitle
Common stock, $0.001 par value per share
CY2023 dei Trading Symbol
TradingSymbol
RSLS
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
5074445
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23457090
CY2023 dei Auditor Firm
AuditorFirmId
49
CY2023 dei Auditor Name
AuditorName
RSM US LLP
CY2023 dei Auditor Location
AuditorLocation
Irvine, California
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4459000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3855000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
100000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
100000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
804000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
410000
CY2023Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
1659000
CY2022Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
2180000
CY2023Q4 us-gaap Inventory Net
InventoryNet
3741000
CY2022Q4 us-gaap Inventory Net
InventoryNet
3611000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
337000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
165000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
10296000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
9911000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
60000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
698000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
250000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
171000
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
28000
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
56000
CY2022Q4 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
260000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
29000
CY2022Q4 rsls Warrant Liability Current
WarrantLiabilityCurrent
344000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
111000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
46000
CY2023Q4 us-gaap Assets
Assets
10663000
CY2022Q4 us-gaap Assets
Assets
11142000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1689000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1926000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1814000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5040000
CY2023Q4 rsls Warrant Liability Current
WarrantLiabilityCurrent
163000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
171000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3777000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7481000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
151000
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
72000
CY2023Q4 us-gaap Liabilities
Liabilities
4000000
CY2022Q4 us-gaap Liabilities
Liabilities
7481000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23457047
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
519219
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
23000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
642302000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
627935000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-635574000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-624187000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-88000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-88000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
6663000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3661000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10663000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11142000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8678000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11240000
CY2023 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3130000
CY2022 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4438000
CY2023 us-gaap Gross Profit
GrossProfit
5548000
CY2022 us-gaap Gross Profit
GrossProfit
6802000
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7548000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14093000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10324000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17250000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2315000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2537000
CY2023 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
777000
CY2022 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
18744000
CY2023 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
33000
CY2022 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-529000
CY2023 us-gaap Operating Expenses
OperatingExpenses
20931000
CY2022 us-gaap Operating Expenses
OperatingExpenses
53153000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-15383000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-46351000
CY2023 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
26000
CY2022 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-113000
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3878000
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
22000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-141000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
122000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11335000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-46594000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
52000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.91
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-380000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11387000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-46214000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1141000
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3457000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
448000
CY2023 rsls Increase Decrease In Warrant Liability
IncreaseDecreaseInWarrantLiability
-182000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-108.90
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5956549
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
424390
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-11387000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-46214000
CY2022 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
4000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
4000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11387000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46210000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
44334000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-46214000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
4000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2087000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
639000
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
318000
CY2022 rsls Stock And Warrants Issued During Period Value Institutional Exercise Of Warrants
StockAndWarrantsIssuedDuringPeriodValueInstitutionalExerciseOfWarrants
2493000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3661000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-11387000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
766000
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10140000
CY2023 rsls Adjustments To Additional Paid In Capital Stock Offering Costs
AdjustmentsToAdditionalPaidInCapitalStockOfferingCosts
-653000
CY2023 rsls Stock And Warrants Issued During Period Value Institutional Exercise Of Warrants
StockAndWarrantsIssuedDuringPeriodValueInstitutionalExerciseOfWarrants
4136000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
6663000
CY2023 us-gaap Profit Loss
ProfitLoss
-11387000
CY2022 us-gaap Profit Loss
ProfitLoss
-46214000
CY2023 us-gaap Depreciation
Depreciation
121000
CY2022 us-gaap Depreciation
Depreciation
330000
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
33000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1823000
CY2023 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
777000
CY2022 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
18744000
CY2023 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
33000
CY2022 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-529000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
766000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
2087000
CY2023 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
395000
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-43000
CY2023 us-gaap Inventory Write Down
InventoryWriteDown
335000
CY2022 us-gaap Inventory Write Down
InventoryWriteDown
579000
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
28000
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-423000
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3878000
CY2023 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-17000
CY2022 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
23000
CY2023 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-125000
CY2022 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-678000
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
465000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1187000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
172000
CY2022 rsls Increase Decrease In Warrant Liability
IncreaseDecreaseInWarrantLiability
-371000
CY2023 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-17000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16960000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21902000
CY2023 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
43000
CY2022 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
131000
CY2023 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
33000
CY2022 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
39000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-92000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13438000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
639000
CY2023 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4136000
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2491000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17574000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3130000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
604000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18860000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3955000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22815000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4559000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3955000
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
10000
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
5000
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 12.25pt;"><i style="font-style:italic;">Use of Estimates </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. </p>
CY2023Q4 rsls Working Capital
WorkingCapital
6500000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4600000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4500000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1700000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
510000
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
61000
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
119000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
155000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
100000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
100000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4459000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3855000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
100000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
100000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4559000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3955000
CY2022Q4 us-gaap Inventory Adjustments
InventoryAdjustments
1000000.0
CY2023Q4 us-gaap Inventory Adjustments
InventoryAdjustments
1000000.0
CY2023 rsls Restocking Fee
RestockingFee
0.10
CY2023 rsls Standard Product Warranty Term
StandardProductWarrantyTerm
P30D
CY2023 us-gaap Advertising Expense
AdvertisingExpense
2200000
CY2022 us-gaap Advertising Expense
AdvertisingExpense
6800000
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 12.25pt;"><i style="font-style:italic;">Concentration of Credit Risk, Interest Rate Risk and Foreign Currency Exchange Rate </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash and trade accounts receivable. Cash and cash equivalents are primarily deposited in demand and money market accounts. At times, such deposits may be in excess of insured limits. Investments in money market funds are not considered to be bank deposits and are not insured or guaranteed by the federal deposit insurance company or other government agency. These money market funds seek to preserve the value of the investment at $1.00 per share; however, it is possible to lose money investing in these funds. The Company has not experienced any losses on its deposits of cash and cash equivalents. To minimize the risk associated with trade accounts receivable, management maintains relationships with the Company’s customers that allow management to monitor current changes in business operations so the Company can respond as needed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Substantially all of the Company’s revenue is denominated in U.S. dollars. Only a small portion of revenue and expenses are denominated in foreign currencies, principally the Australian dollar and Euro for 2023 and 2022. The Company has not entered into any hedging contracts. Future fluctuations in the value of the U.S. dollar may affect the price competitiveness of the Company’s products outside the U.S.</p>
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-635600000
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1020000
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
832000
CY2023Q4 us-gaap Inventory Supplies Net Of Reserves
InventorySuppliesNetOfReserves
1379000
CY2022Q4 us-gaap Inventory Supplies Net Of Reserves
InventorySuppliesNetOfReserves
864000
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1342000
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1915000
CY2023Q4 us-gaap Inventory Net
InventoryNet
3741000
CY2022Q4 us-gaap Inventory Net
InventoryNet
3611000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
110000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
78000
CY2023Q4 rsls Prepaid Patent Expense Current
PrepaidPatentExpenseCurrent
13000
CY2023Q4 us-gaap Prepaid Advertising
PrepaidAdvertising
41000
CY2022Q4 us-gaap Prepaid Advertising
PrepaidAdvertising
3000
CY2023Q4 us-gaap Prepaid Taxes
PrepaidTaxes
47000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
126000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
84000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
337000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
165000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
701000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1829000
CY2023Q4 rsls Accrued Legal Liabilities Current
AccruedLegalLiabilitiesCurrent
200000
CY2022Q4 rsls Accrued Legal Liabilities Current
AccruedLegalLiabilitiesCurrent
1775000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
639000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
316000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
58000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
491000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1814000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5040000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
150000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1029000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
90000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
331000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
60000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
698000
CY2023 us-gaap Depreciation
Depreciation
121000
CY2022 us-gaap Depreciation
Depreciation
330000
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
500000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
6451000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6191000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
260000
CY2022Q4 rsls Indefinite Lived Intangible Assets Excluding Goodwill Before Impairment
IndefiniteLivedIntangibleAssetsExcludingGoodwillBeforeImpairment
20721000
CY2022Q4 rsls Indefinitelivedintangibleassetaccumulatedamortization
Indefinitelivedintangibleassetaccumulatedamortization
20721000
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
33000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1800000
CY2022 rsls Intangible Assets Fair Value Discount Rate
IntangibleAssetsFairValueDiscountRate
0.179
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
300000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
700000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
250000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
171000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
111000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
171000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
151000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
262000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
171000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
228000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
560000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
111000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
115000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
59000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
285000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
23000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
262000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M24D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.069
CY2023 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
0.022
CY2023Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
3.07
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.07
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
139047
CY2022 rsls Class Of Warrant Or Right Grants In Period
ClassOfWarrantOrRightGrantsInPeriod
145192
CY2022 rsls Class Of Warrant Or Right Exercised In Period
ClassOfWarrantOrRightExercisedInPeriod
84614
CY2022 rsls Class Of Warrant Or Right Cancelled In Period
ClassOfWarrantOrRightCancelledInPeriod
6149
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
193476
CY2023 rsls Class Of Warrant Or Right Grants In Period
ClassOfWarrantOrRightGrantsInPeriod
35912718
CY2023 rsls Class Of Warrant Or Right Exercised In Period
ClassOfWarrantOrRightExercisedInPeriod
20507676
CY2023 rsls Class Of Warrant Or Right Cancelled In Period
ClassOfWarrantOrRightCancelledInPeriod
126
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
15598392
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8678000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11240000
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
0.019
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.043
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
767000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2087000
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-293000
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-76000
CY2023 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
28000
CY2022 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-54000
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
28000
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-423000
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
30000
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
7000
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
9000
CY2023 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
17000
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
4000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
52000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-380000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.059
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.038
CY2023 rsls Effectiveincometaxratereconciliationdeductionsstockwarrantvaluation
Effectiveincometaxratereconciliationdeductionsstockwarrantvaluation
0.097
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.003
CY2023 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.027
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.002
CY2023 rsls Effective Income Tax Rate Reconciliation Net Operating Loss Adjustment Percent
EffectiveIncomeTaxRateReconciliationNetOperatingLossAdjustmentPercent
0.063
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.008
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.028
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.348
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.250
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.005
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.008
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1052000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1052000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1052000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1052000
CY2023Q4 rsls Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
1096000
CY2022Q4 rsls Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
1137000
CY2023Q4 rsls Deferred Tax Assets Capitalized Research And Development Costs
DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
170000
CY2022Q4 rsls Deferred Tax Assets Capitalized Research And Development Costs
DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
272000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
751000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
1157000
CY2023Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
56000
CY2023Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
4420000
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
4597000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2492000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2492000
CY2023Q4 rsls Deferred Tax Asset Lease Liability
DeferredTaxAssetLeaseLiability
70000
CY2022Q4 rsls Deferred Tax Asset Lease Liability
DeferredTaxAssetLeaseLiability
43000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
67930000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
63424000
CY2023Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
2000
CY2022Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
2000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
76987000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
73124000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
76895000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
72945000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
92000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
179000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
80000
CY2023Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
64000
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
43000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
64000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
123000
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
28000
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
56000
CY2022Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2023Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023Q4 rsls Severance Benefits Payable
SeveranceBenefitsPayable
800000
CY2023Q4 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
900000
CY2023 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-004559-index-headers.html Edgar Link pending
0001558370-24-004559-index.html Edgar Link pending
0001558370-24-004559.txt Edgar Link pending
0001558370-24-004559-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rsls-20231231.xsd Edgar Link pending
rsls-20231231x10k.htm Edgar Link pending
rsls-20231231x10k003.jpg Edgar Link pending
rsls-20231231xex10d6.htm Edgar Link pending
rsls-20231231xex21d1.htm Edgar Link pending
rsls-20231231xex23d1.htm Edgar Link pending
rsls-20231231xex31d1.htm Edgar Link pending
rsls-20231231xex31d2.htm Edgar Link pending
rsls-20231231xex32d1.htm Edgar Link pending
rsls-20231231xex32d2.htm Edgar Link pending
rsls-20231231xex97d1.htm Edgar Link pending
rsls-20231231xex97d1001.jpg Edgar Link pending
rsls-20231231xex97d1002.jpg Edgar Link pending
Show.js Edgar Link pending
rsls-20231231_pre.xml Edgar Link unprocessable
rsls-20231231x10k_htm.xml Edgar Link completed
rsls-20231231_cal.xml Edgar Link unprocessable
rsls-20231231_def.xml Edgar Link unprocessable
rsls-20231231_lab.xml Edgar Link unprocessable